Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flurbiprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.97 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | FABP2 | P12104 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flurbiprofen SCHEMBL2472737 | 0.98 | AKR1C3 (0.94) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL29350102 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Esflurbiprofen SCHEMBL505817 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL1070292 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754830 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL10029029 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8755275 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754978 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL26131 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL2248 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171490-A1 | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients | PHARMALINGT INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-1755616-B1 | Treatment of exudative retinopathy with mineralcorticoids | ADVANCED OCULAR SYSTEMS LTD (AU) | 2013-08-14 | — | — | EP | disclosed |
| US-20110054031-A1 | Ophthalmic NSAIDS as Adjuvants | ISTA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2247289-A2 | OPHTHALMIC NSAIDS AS ADJUVANTS | Ista Pharmaceuticals (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009105534-A2 | OPHTHALMIC NSAIDS AS ADJUVANTS | ISTA PHARMACEUTICALS (US) | 2009-08-27 | — | — | WO | disclosed |
| EP-2074994-A1 | Enhanced ocular neuroprotection/neurostimulation | Minu, L.L.C. (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1904056-B1 | Use of a macrolide to restore corneal sensation | MINU LLC (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1904056-A2 | ENHANCED OCULAR NEUROPROTECTION/NEUROSTIMULATION | Minu, L.L.C. (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1848541-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Pharmalight Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007038453-A2 | USE OF AN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENT TO AMELIORATE INFLAMMATION | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2007-04-05 | — | — | WO | disclosed |
| EP-1718314-A1 | HEPARIN FOR THE TREATMENT OF OCULAR PATHOLOGIES | Advanced Ocular Systems Limited (AU) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006082588-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | PHARMALIGHT INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060122152-A1 | Heparin for the treatment of ocular pathologies | MINU, LLC | 2006-06-08 | — | — | US | disclosed |
| US-20050261243-A1 | Antiprostaglandins for the treatment of ocular pathologies | MINU, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20050256081-A1 | Tetracycline derivatives for the treatment of ocular pathologies | MINU, LLC | 2005-11-17 | — | — | US | disclosed |
| WO-2005102303-A2 | ANTIPROSTAGLANDINS FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-11-03 | — | — | WO | disclosed |
| US-20050245497-A1 | Treatment of ophthalmic conditions | EYE CO PTY LTD (AU) | 2005-11-03 | — | — | US | disclosed |
| WO-2005099715-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD. (AU) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005082380-A1 | HEPARIN FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082376-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054031-A1 | Ophthalmic NSAIDS as Adjuvants | VEGFA, ALOX5, KDR | PTGS1 15/4885PTGS2 26/4885AKR1C3 878/4885 |
| US-20050245497-A1 | Treatment of ophthalmic conditions | MC2R, NR3C2, PTGIR | PTGS1 14/4885PTGS2 48/4885AKR1C3 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.